Three 2026 Breakthrough Prize winners reflect on developing Luxturna, a gene therapy that treats blindness caused by rare ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely ...

Over 24 months, patients with dry age‑related macular degeneration (AMD) who received light therapy with three wavelengths gained clarity of vision, had a reduced incidence of new geographic atrophy, ...

The biotechnology company disclosed interim human trial data for its RV-001 optogenetic treatment aiming to restore sight in ...

Vision is one of the most crucial human senses, yet more than 300 million people worldwide are at risk of vision loss due to various retinal diseases. While recent advancements in retinal disease ...

The growing body of clinical evidence for RevitalVision supports the integration of perceptual learning into routine ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...

Please provide your email address to receive an email when new articles are posted on . The programs are designed to provide anti-VEGF treatment for patients who are uninsured or underinsured.

Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis ...

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision ...